Effects of zanubrutinib: A Synthesis of Findings from 15 Studies
- Home
- Effects of zanubrutinib
This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of zanubrutinib: A Synthesis of Findings from 15 Studies", please consult your doctor.
For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
Major Research Findings
Zanubrutinib has shown promising results in treating chronic lymphocytic leukemia (CLL). It is a second-generation Bruton’s tyrosine kinase (BTK) inhibitor that has demonstrated improved safety and efficacy compared to the first-generation BTK inhibitor, ibrutinib. 3 The SEQUOIA study found that zanubrutinib significantly extended progression-free survival (PFS) in treatment-naive CLL patients compared to bendamustine-rituximab (BR). 11 Moreover, the ALPINE trial directly compared zanubrutinib with ibrutinib and revealed that zanubrutinib has a better safety profile and greater clinical efficacy. 3 Additionally, zanubrutinib has shown effectiveness in treating relapsed or refractory CLL/small lymphocytic lymphoma (SLL). 7 Further studies suggest its potential benefit in treating relapsed or refractory follicular lymphoma. 1 While zanubrutinib has demonstrated positive outcomes, it’s important to note that it can cause side effects like bleeding. 10 There are also reports of dermatological toxicities associated with zanubrutinib. 2
Benefits and Risks
Benefit Summary
Zanubrutinib exhibits improved safety and efficacy in treating CLL and other B-cell malignancies. 3 It possesses greater BTK selectivity than ibrutinib, leading to fewer side effects and enhanced efficacy. 3 Studies have demonstrated its ability to significantly prolong PFS in CLL patients. 3 11 Furthermore, zanubrutinib has proven more effective than ibrutinib in treating relapsed or refractory CLL/SLL patients. 7 Research indicates its potential benefits in managing relapsed or refractory follicular lymphoma. 1
Risk Summary
Zanubrutinib carries potential side effects like bleeding. 10 Dermatological toxicities have also been reported in association with zanubrutinib. 2
Comparison of Studies
Commonalities of Studies
Numerous studies consistently highlight zanubrutinib’s superior safety and efficacy in treating CLL. 3 11 7
Differences in Studies
Different studies present varied findings regarding zanubrutinib’s side effects. 10 2 5 Furthermore, the efficacy of zanubrutinib also varies across different research studies. 3 11 7 1
Consistency and Contradictions in Results
Multiple studies consistently demonstrate zanubrutinib’s effectiveness and safety in managing CLL. 3 11 7 However, there are discrepancies in findings regarding zanubrutinib’s side effects. 10 2 5 Additionally, research on zanubrutinib’s efficacy also exhibits variability. 3 11 7 1
Considerations for Real-World Applications
Zanubrutinib is emerging as a promising treatment option for CLL, exhibiting improved safety and efficacy. 3 11 7 However, it’s crucial to remain aware of potential side effects like bleeding. 10 Furthermore, dermatological toxicities have been observed in some cases. 2 Therefore, it’s essential for healthcare professionals to carefully monitor patients receiving zanubrutinib therapy for any potential side effects. 10 2 5
Limitations of Current Research
The research on zanubrutinib’s efficacy and safety remains limited. 3 11 7 Moreover, the long-term impact of zanubrutinib is not fully understood. 3 11 7
Future Research Directions
Further research is needed to assess the long-term effects of zanubrutinib. 3 11 7 Investigating methods to mitigate zanubrutinib’s side effects is also crucial. 10 2 5
Conclusion
Zanubrutinib emerges as a promising treatment for CLL, exhibiting enhanced safety and efficacy compared to earlier BTK inhibitors. 3 11 7 However, potential side effects like bleeding and dermatological toxicities necessitate vigilant monitoring during treatment. 10 2 5 Future research will continue to shed light on zanubrutinib’s long-term impact and explore ways to improve its safety profile. 10 2 5
Benefit Keywords
Risk Keywords
Article Type
Author: ZinzaniPier Luigi, MayerJiří, FlowersChristopher R, BijouFontanet, De OliveiraAna C, SongYuqin, ZhangQingyuan, MerliMichele, BouabdallahKrimo, GanlyPeter, ZhangHuilai, JohnsonRoderick, Martín García-SanchoAlejandro, Provencio PullaMariano, TrněnýMarek, YuenSam, TillyHerve, KingsleyEdwin, TumyanGayane, AssoulineSarit E, AuerRebecca, IvanovaElena, KimPil, HuangSha, DelarueRichard, TrotmanJudith
Language : English
Case report: Zanubrutinib-induced dermatological toxicities: A single-center experience and review.
Author: WangLingling, TangJiao, FengJun, HuangYongfen, ChengYuexin, XuHao, MiaoYuqing
Language : English
Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option.
Author: MolicaStefano, TamConstantine, AllsupDavid, PolliackAaron
Language : English
Author: SarosiekShayna, CastilloJorge J
Language : English
Author: WalshMadalyn, XuAlice, BallasZuhair, SanchezRolando
Language : English
Author: IslamPrioty
Language : English
Author: BrownJennifer R, EichhorstBarbara, HillmenPeter, JurczakWojciech, KaźmierczakMaciej, LamannaNicole, O'BrienSusan M, TamConstantine S, QiuLugui, ZhouKeshu, SimkovicMartin, MayerJiri, Gillespie-TwardyAmanda, FerrajoliAlessandra, GanlyPeter S, WeinkoveRobert, GrosickiSebastian, MitalAndrzej, RobakTadeusz, OsterborgAnders, YimerHabte A, SalmiTommi, WangMegan-Der-Yu, FuLina, LiJessica, WuKenneth, CohenAileen, ShadmanMazyar
Language : English
Author: ChristensenBradley W, ZahaVlad G, AwanFarrukh T
Language : English
Author: TariqBilal, ContoStephanie, CohenAileen, SahasranamanSrikumar, OuYing C
Language : English
Author: JiangDan, SongZaiwei, HuYang, DongFei, ZhaoRongsheng
Language : English
Author: TamConstantine S, BrownJennifer R, KahlBrad S, GhiaPaolo, GiannopoulosKrzysztof, JurczakWojciech, ŠimkovičMartin, ShadmanMazyar, ÖsterborgAnders, LaurentiLuca, WalkerPatricia, OpatStephen, ChanHenry, CiepluchHanna, GreilRichard, TaniMonica, TrněnýMarek, BranderDanielle M, FlinnIan W, GrosickiSebastian, VernerEmma, TedeschiAlessandra, LiJianyong, TianTian, ZhouLei, MarimpietriCarol, PaikJason C, CohenAileen, HuangJane, RobakTadeusz, HillmenPeter
Language : English
Author: EasawSaumya, EzzatiShawyon, CoombsCatherine C
Language : English
Author: XuWei, YangShenmiao, TamConstantine S, SeymourJohn F, ZhouKeshu, OpatStephen, QiuLugui, SunMingyuan, WangTingyu, TrotmanJudith, PanLing, GaoSujun, ZhouJianfeng, ZhouDaobin, ZhuJun, SongYuqin, HuJianda, FengRu, HuangHaiwen, SuDan, ShiMiao, LiJianyong
Language : English
Author: ZhuWeiguo, TaoShi, MiaoWenchun, LiuHui, YuanXianggui
Language : English
Author: RobakEwa, RobakTadeusz
Language : English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.